Advertisement

Fibrosis pp 91-116 | Cite as

Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension

  • Sabine Klein
  • Robert Schierwagen
  • Frank Erhard Uschner
  • Jonel Trebicka
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1627)

Abstract

Portal hypertension either develops due to progressive liver fibrosis or is the consequence of vascular liver diseases such as portal vein thrombosis or non-cirrhotic portal hypertension. This chapter focuses on different rodent models of liver fibrosis with portal hypertension and also in few non-cirrhotic portal hypertension models. Importantly, after the development of portal hypertension, the proper assessment of drug effects in the portal and systemic circulation should be discussed. The last part of the chapter is dedicated in these techniques to assess the in vivo hemodynamics and the ex vivo techniques of the isolated liver perfusion and vascular contractility.

Key words

Portal hypertension Bile duct ligation Carbon tetrachloride Methionine-choline-deficient diet High-fat diet Partial portal vein ligation Colored microsphere technique Isolated in situ liver perfusion Aortic ring contraction 

Notes

Acknowledgment

The Laboratory is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), the H. J. & W. Hector Stiftung, Ernst-Bertha-Grimmke-Stiftung (6/15) and European Union’s Horizon 2020 research and innovation programme (No 668031).

References

  1. 1.
    Trebicka J, Hennenberg M, Laleman W et al (2007) Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46(1):242–253. doi: 10.1002/hep.21673 CrossRefPubMedGoogle Scholar
  2. 2.
    Trebicka J, Leifeld L, Hennenberg M et al (2008) Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47(4):1264–1276. doi: 10.1002/hep.22170 CrossRefPubMedGoogle Scholar
  3. 3.
    Trebicka J, Hennenberg M, Odenthal M et al (2010) Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53(4):702–712. doi: 10.1016/j.jhep.2010.04.025 CrossRefPubMedGoogle Scholar
  4. 4.
    Granzow M, Schierwagen R, Klein S et al (2014) Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60(1):334–348. doi: 10.1002/hep.27117 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Klein S, Herath CB, Schierwagen R et al (2015) Hemodynamic effects of the non-peptidic angiotensin-(1-7) agonist AVE0991 in liver cirrhosis. PLoS One 10(9):e0138732. doi: 10.1371/journal.pone.0138732
  6. 6.
    Klein S, Rick J, Lehmann J et al (2015) Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut. doi: 10.1136/gutjnl-2015-309600 PubMedGoogle Scholar
  7. 7.
    Schierwagen R, Maybuchen L, Zimmer S et al (2015) Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep 5:12931. doi: 10.1038/srep12931 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Uschner FE, Ranabhat G, Choi SS et al (2015) Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep 5:14573. doi: 10.1038/srep14573 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Klein S, Hinuber C, Hittatiya K et al (2016) Novel rat model of repetitive portal venous embolization mimicking human non-cirrhotic idiopathic portal hypertension. PLoS One 11(9):e0162144. doi: 10.1371/journal.pone.0162144 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Heller J, Trebicka J, Shiozawa T et al (2005) Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int 25(3):657–666. doi: 10.1111/j.1478-3231.2005.01053.x CrossRefPubMedGoogle Scholar
  11. 11.
    Hennenberg M, Biecker E, Trebicka J et al (2006) Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 130(3):838–854. doi: 10.1053/j.gastro.2005.11.029 CrossRefPubMedGoogle Scholar
  12. 12.
    Zhou Q, Hennenberg M, Trebicka J et al (2006) Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55(9):1296–1305. doi: 10.1136/gut.2005.081059 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hennenberg M, Trebicka J, Biecker E et al (2007) Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 45(2):495–506. doi: 10.1002/hep.21502 CrossRefPubMedGoogle Scholar
  14. 14.
    Trebicka J, Hennenberg M, Schulze Probsting A et al (2009) Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 50(6):1924–1935. doi: 10.1002/hep.23222 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Sabine Klein
    • 1
  • Robert Schierwagen
    • 2
  • Frank Erhard Uschner
    • 3
  • Jonel Trebicka
    • 4
  1. 1.Laboratory for Liver Fibrosis and Portal Hypertension, Department of Internal Medicine IUniversity of Clinic BonnBonnGermany
  2. 2.European Foundation for the Study of Chronic Liver FailureBarcelonaSpain
  3. 3.Faculty of Health SciencesUniversity of Southern DenmarkOdenseDenmark
  4. 4.Institute for Bioengineering of CataloniaBarcelonaSpain

Personalised recommendations